Arsanis (NASDAQ:ASNS) was downgraded by investment analysts at Piper Jaffray Companies from an “overweight” rating to a “neutral” rating in a research note issued to investors on Thursday, The Fly reports.
Other analysts have also issued research reports about the stock. Zacks Investment Research raised shares of Arsanis from a “hold” rating to a “buy” rating and set a $27.00 price target on the stock in a research report on Tuesday, April 3rd. Cantor Fitzgerald set a $26.00 price target on shares of Arsanis and gave the company a “buy” rating in a research report on Thursday, March 15th. Finally, ValuEngine raised shares of Arsanis from a “sell” rating to a “hold” rating in a research report on Wednesday, May 2nd. Three research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The company has a consensus rating of “Buy” and an average target price of $25.25.
Shares of Arsanis traded down $13.39, hitting $4.80, during midday trading on Thursday, according to Marketbeat. The company’s stock had a trading volume of 47,820 shares, compared to its average volume of 42,524. Arsanis has a one year low of $10.40 and a one year high of $28.69. The company has a quick ratio of 7.38, a current ratio of 7.38 and a debt-to-equity ratio of 0.20. The firm has a market cap of $260.59 million and a P/E ratio of -0.29.
Arsanis (NASDAQ:ASNS) last posted its quarterly earnings results on Thursday, May 10th. The company reported ($0.74) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.04) by $0.30. equities analysts expect that Arsanis will post -4.55 EPS for the current year.
Institutional investors have recently bought and sold shares of the stock. New York State Common Retirement Fund bought a new stake in Arsanis during the 1st quarter worth approximately $114,000. California State Teachers Retirement System bought a new stake in Arsanis during the 1st quarter worth approximately $162,000. Schwab Charles Investment Management Inc. bought a new stake in Arsanis during the 1st quarter worth approximately $200,000. Millennium Management LLC bought a new stake in Arsanis during the 4th quarter worth approximately $299,000. Finally, Landscape Capital Management L.L.C. bought a new stake in Arsanis during the 4th quarter worth approximately $504,000. 71.60% of the stock is currently owned by institutional investors and hedge funds.
Arsanis, Inc, a clinical-stage biopharmaceutical company, focuses on applying monoclonal antibody (mAb) immunotherapies to address infectious diseases. Its lead product candidate is ASN100, a mAb therapeutic in Phase II clinical development for the prevention of staphylococcus aureus pneumonia in mechanically ventilated patients.
Receive News & Ratings for Arsanis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arsanis and related companies with MarketBeat.com's FREE daily email newsletter.